Cite
MLA Citation
M Friedlander et al.. “Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy.” Annals of oncology, vol. 29, 2018, pp. 737–743. http://access.bl.uk/ark:/81055/vdc_100095514415.0x000039